Future of ToxicologyIron Chelators and Differing Modes of Action and Toxicity: The Changing Face of Iron Chelation Therapy
The DOI matches its Crossref record; 16 of the 16 references it cites were found in a registry or an index.
Abstract
Iron (Fe) chelation therapy was initially designed to alleviate the toxic effects of excess Fe evident in Fe-overload diseases. However, the novel toxicological properties of some Fe chelator-metal complexes have shifted appreciable focus to their application in cancer chemotherapy. Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as chemotherapeutics against cancer. Within this perspective, we discuss the different modes of action and toxicological profiles of Fe chelators, including analogues of 2-pyridylcarboxaldehyde isonicotinoyl hydrazone, di-2-pyridylketone isonicotinoyl hydrazone, di-2-pyridylketone thiosemicarbazone, and the clinically trialed chelator 3-aminopyridine-2-carboxaldehyde thiosemicarbazone. The potential application of these agents in the changing face of Fe chelation therapy is discussed.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Kalinowski and Richardson have recently reviewed synthetic chelators based on various chelating chemical groupings such as catechol, hydroxamate, and hydroxypyridinone, concluding that structures providing hexadentate hydroxypyridinone functionality (an example being deferiprone) have particular promise as bacteriostatic agents in relation to outcompeting siderophores of microbes [49].”
From The utility of iron chelators in the management of inflammatory disorders (2015) · cites this paper as [49]
Citations
Cites
Free Radicals in Biology and Medicine
Land, E. T. (1990) · International Journal of Radiation Biology · doi:10.1080/09553009014552071 · Cited by 4,854
Neurodegenerative diseases and oxidative stress
Barnham, K. J., Masters, C. L., & Bush, A. I. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1330 · Cited by 3,683
Thelander, L., & Reichard, P. (1979) · Annual Review of Biochemistry · doi:10.1146/annurev.bi.48.070179.001025 · Cited by 1,167
The Evolution of Iron Chelators for the Treatment of Iron Overload Disease and Cancer
Kalinowski, D. S., & Richardson, D. R. (2005) · Pharmacological Reviews · doi:10.1124/pr.57.4.2 · Cited by 721
Self-citationRichardson, D. R., Sharpe, P. C., Lovejoy, D. B., Senaratne, D., Kalinowski, D. S., Islam, M., & Bernhardt, P. V. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0606342 · Cited by 383
Self-citationLe, N. T. V., & Richardson, D. R. (2004) · Blood · doi:10.1182/blood-2004-05-1866 · Cited by 321
Self-citationFinch, R. A., Liu, M.-C., Cory, A. H., Cory, J. G., & Sartorelli, A. C. (1999) · Advances in Enzyme Regulation · doi:10.1016/s0065-2571(98)00017-x · Cited by 223
Chaston, T. B., Lovejoy, D. B., Watts, R., & Richardson, D. R. (2003) · PubMed · Cited by 221
Self-citationChelators at the cancer coalface: Desferrioxamine to Triapine and beyond
Yu, Y., Wong, J., Lovejoy, D. B., Kalinowski, D. S., & Richardson, D. R. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1954 · Cited by 195
Self-citationWadler, S., Makower, D., Clairmont, C., Lambert, P., Fehn, K., & Sznol, M. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.158 · Cited by 139
Research works printed but not linked: 28
- Liu Z. D., 2002, Med. Res. Rev., 22, 64
- Lovejoy D. B., 2000, Complexes of gallium(III) and other metal ions and their potential in the treatment of neoplasia. Expert Opin. Invest. Drugs 9, 1257−1270
- Olivieri N. F., 1997, Iron-chelating therapy and the treatment of thalassemia. Blood 89, 739−761
- Wong A., 1999, The Friedreich's ataxia mutation confers cellular sensitivity to oxidant stress which is rescued by chelators of iron and calcium and inhibitors of apoptosis. Hum. Mol. Genet. 8, 425−430
- Shinar E., 1990, Semin. Hematol., 27, 82
- Kolberg M., 2004, Biochim. Biophys. Acta, 1699, 34
- Thelander L., 1983, Continual presence of oxygen and iron required for mammalian ribonucleotide reduction: possible regulation mechanism. Biochem. Biophys. Res. Commun. 110, 859−865
- Gao J., 2001, IV: The mechanisms involved in inhibiting cell-cycle progression. Blood 98, 842−850.
- Nurtjahja-Tjendraputra E., 2006, Iron chelation regulates cyclin D1 expression via the proteasome: a link to iron deficiency-mediated growth suppression. Blood, in press
- Armstrong C. M., 2003, Eur. J. Inorg. Chem., 2003
- Wong C. S., 2004, Biochim. Biophys. Acta, 1739, 80
- Richardson D. R., 2001, Biochim. Biophys. Acta, 1536
- Chaston T. B., 2004, Potent antitumor activity of novel iron chelators derived from di-2-pyridylketone isonicotinoyl hydrazone involves fenton-derived free radical generation. Clin. Cancer Res. 10, 7365−7374
- Sartorelli A. C., 1971, Mechanism of inhibition of ribonucleoside diphosphate reductase by α-(N)-heterocyclic aldehyde thiosemicarbazones. Biochem. Pharmacol. 20, 3119−3123
- Sartorelli A. C., 1967, Inhibition of the growth of sarcoma 180 ascites cells by combinations of inhibitors of nucleic acid biosynthesis and the cupric chelate of kethoxal bis-(thiosemicarbazone). Cancer Res. 27, 1614−1619
- Agrawal K. C., 1978, The chemistry and biological activity of α-(N)-heterocyclic carboxaldehyde thiosemicarbazones. Prog. Med. Chem. 15, 321−356
- Yuan J., 2004, Novel di-2-pyridyl-derived iron chelators with marked and selective antitumor activity: in vitro and in vivo assessment. Blood 104, 1450−1458
- Whitnall M., 2006, Proc. Natl. Acad. Sci. U.S.A. 103
- Shao J., 2006, A Ferrous-Triapine complex mediates formation of reactive oxygen species that inactivate human ribonucleotide reductase. Mol. Cancer. Ther. 5, 586−592
- Cory J. G., 1994, Inhibitors of ribonucleotide reductase: Comparative effects of amino- and hydroxy-substituted pyridine-2-carboxaldehyde thiosemicarbazones. Biochem. Pharmacol. 48, 335−344
- Finch R. A., 2000, Triapine (3-aminopyridine-2-carboxaldehyde-thiosemicarbazone): a potent inhibitor of ribonucleotide reductase activity with broad spectrum antitumor activity. Biochem. Pharmacol. 59, 983−991
- Shao J., 2004, Cancer Res., 64, 6
- Cooper C. E., 1996, J. Biol. Chem., 271
- Chen C. H., 2002, Eur. J. Cancer, 38, S26
- Yen Y., 2004, A phase I trial of 3-aminopyridine-2-carboxaldehyde thiosemicarbazone in combination with gemcitabine for patients with advanced cancer. Cancer Chemother. Pharmacol. 54, 331−342
- Liu Z. D., 2002, Coord. Chem. Rev., 232
- Richardson D. R., 1995, The potential of iron chelators of the pyridoxal isonicotinoyl hydrazone class as effective antiproliferative agents. Blood 86, 4295−4306
- Abbreviations AP, 3-aminopyridine-2-carboxaldehyde thiosemicarbazone
Cited by
Items 101–143 of 143
The effects of lactoferrin in a rat model of catecholamine cardiotoxicity
Mladěnka, P., Semecký, V., Bobrovová, Z., Nachtigal, P., Vávrová, J., Holečková, M., Palička, V., Mazurová, Y., & Hrdina, R. (2008) · BioMetals · doi:10.1007/s10534-008-9172-5 · Cited by 17
“have been well documented to alleviate the toxic effects of excess iron in various pathological conditions, where abundant iron may participate on ROS propagation ( Kalinowski and Richardson 2007; Kontoghiorghes 2006; Sterba et al. 2007).”
BackgroundSalehi, S., Saljooghi, A. S., & Shiri, A. (2016) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2016.04.026 · Cited by 18
Metal-Based Anticancer Complexes and p53: How Much Do We Know?
Alfadul, S. M., Matnurov, E. M., Varakutin, A. E., & Babak, M. V. (2023) · Cancers · doi:10.3390/cancers15102834 · Cited by 16
“- re- etallation and activation of utant p53 - in vitro activity and in vivo efficacy in cells and tu ors ith Zndeficient p53R172H allele [48,58,59,63,64,68]”
BackgroundInfluentialWijesinghe, T. P., Kaya, B., Gonzálvez, M. A., Harmer, J. R., Azad, M. G., Bernhardt, P. V., Dharmasivam, M., & Richardson, D. R. (2023) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.3c01612 · Cited by 16
Self-citationManikandan, R., & Viswnathamurthi, P. (2012) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2012.07.028 · Cited by 15
Gullbo, J., Fryknäs, M., Rickardson, L., D’Arcy, P., Hägg, M., Wickström, M., Hassan, S., Westman, G., Brnjic, S., Nygren, P., et al. (2011) · Biochemical Pharmacology · doi:10.1016/j.bcp.2011.04.003 · Cited by 14
“ROS generation could lead to several toxicological consequences as a result of oxidative injury to important biomolecules such as DNA, proteins and lipids [33].”
BackgroundDharmasivam, M., Zhang, S., Zhao, X., Richardson, V., Wijesinghe, T. P., Süleymanoğlu, M., Azad, M. G., Bernhardt, P. V., Kaya, B., & Richardson, D. R. (2025) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5c00374 · Cited by 13
Self-citationBernhardt, P. V., Gonzálvez, M. A., & Martı́nez, M. (2017) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.7b02381 · Cited by 13
Iodide-enhanced Cu-MOF nanomaterials for the amplified colorimetric detection of Fe 3+
Guan, Y., Zhao, X., Li, Q., Huang, L., Yang, J., Yang, T., Yang, Y., & Hu, R. (2021) · Analytical Methods · doi:10.1039/d1ay01612a · Cited by 13
Kovacic, P., & Somanathan, R. (2010) · Journal of Receptors and Signal Transduction · doi:10.3109/10799890903582578 · Cited by 13
“Redox-inactive Fe chelator complexes are well suited for the treatment of Fe-overload diseases, whereas Fe chelator complexes with high redox activity have shown promising results as anticancer agents (18).”
BackgroundKaya, B., Smith, H., Chen, Y., Azad, M. G., Russell, T. M., Richardson, V., Dharmasivam, M., & Richardson, D. R. (2024) · Inorganic Chemistry · doi:10.1021/acs.inorgchem.4c03642 · Cited by 12
Self-citationAn overview on ligands of therapeutically interest
Martín, J. (2018) · Pharmacy & Pharmacology International Journal · doi:10.15406/ppij.2018.06.00177 · Cited by 14
Kheirkhahi, M., Shaabani, B., & Kafil, H. S. (2021) · Journal of the Iranian Chemical Society · doi:10.1007/s13738-021-02281-1 · Cited by 10
Mousavi, Z., Ghasemi, J. B., Ziarani, G. M., Rahimi, S., & Badiei, A. (2024) · Discover Nano · doi:10.1186/s11671-024-04013-9 · Cited by 9
Zhang, Z.-H., Zhang, X., Wang, P., Xu, S.-H., Liang, Z., Ye, C., & Wang, X. (2024) · Spectrochimica Acta Part A Molecular and Biomolecular Spectroscopy · doi:10.1016/j.saa.2024.124834 · Cited by 9
Unraveling the chemistry of ionic liquid mediated carbon dots as sensing probe – A review
Junaid, H. M., Munir, S., & Batool, M. (2023) · Trends in Environmental Analytical Chemistry · doi:10.1016/j.teac.2023.e00214 · Cited by 7
Amereh, M., Seyfoori, A., Shojaei, S., Lane, S., Zhao, T., Barough, M. S., Lum, J. J., Walter, P. B., & Akbari, M. (2025) · Advanced Science · doi:10.1002/advs.202412505 · Cited by 7
Liu, X., Yao, H., Li, N., Xu, M., Jiang, C., Chen, Z., Wang, Y., & Shi, H. (2020) · Tetrahedron · doi:10.1016/j.tet.2020.131626 · Cited by 7
Synthesis and Antibacterial Activity of Novel Hydroxy Semicarbazone Derivatives.
Hariri, E., Mahboubi, A., Fathi, M., Rahmani, P., Tehrani, K. H. M. E., Babaeian, M., Mashayekhi, V., & Kobarfard, F. (2016) · PubMed Central · Cited by 6
Akladios, F. N., Andrew, S. D., & Parkinson, C. J. (2016) · BioMetals · doi:10.1007/s10534-016-9945-1 · Cited by 6
“Keywords Copper Thiosemicarbazone Metal chelation Metal transport Cisplatin Melanoma Reactive oxygen species (ROS)”
BackgroundFluorescent Probe for Recognizing Fe3+ in Aqueous Solutions and its Applications
Li, S., Kong, X., Wang, Q., Fang, J., Fu, C., Zhang, X., Jia, J., & Chen, Y. (2025) · Journal of Fluorescence · doi:10.1007/s10895-025-04595-2 · Cited by 5
Ni, C., Guo, Z., Bu, H., Zhao, X., Bao, M., Ding, L., Liang, C., Tang, Q., & Li, J. (2024) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2024.111092 · Cited by 5
Iron Metabolism in Cancer and Infection
Nekhai, S. A., & Gordeuk, V. R. (2011) · Humana Press eBooks · doi:10.1007/978-1-60327-485-2_24 · Cited by 6
Adhikari, A., Mukherjee, S., Chakraborty, A. K., Biswas, S., Basu, A., Chakraborty, M., Chattopadhyay, S., Das, D., & Chattopadhyay, D. (2022) · Journal of Photochemistry and Photobiology A Chemistry · doi:10.1016/j.jphotochem.2022.114000 · Cited by 4
Dharmasivam, M., Faiz, S., Kaya, B., Wijesinghe, T. P., Süleymanoğlu, M., Azad, M. G., Richardson, V., Zahoor, A. F., Kalinowski, D. S., Lewis, W., et al. (2026) · Chemical Science · doi:10.1039/d5sc06084b · Cited by 3
Self-citationChromogenic and fluorogenic Schiff base sensors
Nazir, F., Musawar, S. S., Khan, A. A., Akram, B., & Ahmed, F. (2025) · Chinese Journal of Structural Chemistry · doi:10.1016/j.cjsc.2025.100751 · Cited by 3
Chen, Q., Luo, C., Ma, Q., Yan, X., & Cai, X. (2021) · Journal of Applied Polymer Science · doi:10.1002/app.51966 · Cited by 3
Xie, Z., Sun, J., Zhou, Z., & Xia, S. (2021) · Materiali in tehnologije · doi:10.17222/mit.2020.160 · Cited by 2
Synthesis of gemini triethylene-tetramine bridged bis-tridentate iron(III) chelators
Rodríguez‐Lucena, D., Schalk, I. J., & Mislin, G. L. A. (2011) · Tetrahedron · doi:10.1016/j.tet.2011.01.008 · Cited by 2
Neguța, E., Bălan, G., Shova, S. G., Gulea, A., Cotovaia, A., & Bulimestru, I. (2024) · Akademos · doi:10.52673/18570461.23.4-71.03 · Cited by 1
Pavankumar, B. B., Ranjan, P., Jha, P. C., & Sivaramakrishna, A. (2022) · ChemistrySelect · doi:10.1002/slct.202201875 · Cited by 1
Bakir, M., & Gyles, C. (2011) · Journal of Coordination Chemistry · doi:10.1080/00958972.2011.583645
Crystal structure of 3-benzyl-1-[(cyclohexylidene)amino]thiourea
Mohamed, S. K., Mague, J. T., Akkurt, M., Hassan, A. A., Abdel‐Aziz, A. T., & Albayati, M. R. (2015) · Acta Crystallographica Section E Crystallographic Communications · doi:10.1107/s205698901502112x
“Both thiosemicarbazones and their metal complexes have been studied as potential antiviral, antibacterial, antimycobacterial, antiprotozoal, antifungal, and antineoplastic agents (Kalinowski & Richardson, 2005; Kalinowski & Richardson, 2007; Smee & Sidwell, 2003; Pandeya et al., 1999).”
BackgroundGraur, V., Graur, V., & Граур, В. (2015) · DOAJ (DOAJ: Directory of Open Access Journals)
Oyetunji, O. A., Gontse, R., & Nareetsile, F. (2020) · International Journal of Chemical Studies · doi:10.22271/chemi.2020.v8.i3a.9460
Iron Metabolism: From Inflammation to Cancer
Paola, A. D., Tortora, C., Argenziano, M., Leva, C. D., & Rossi, F. (2021) · Annals of Hematology & Oncology · doi:10.26420/annhematoloncol.2021.1351
“As regards the synthetic compounds, Kalinowski and Richardson already in 2007 described the effectiveness of Deferiprone (DFP) as bacteriostatic agent, since its capability to contrast iron overload and thus also inflammation and infection [79].”
BackgroundMeyboom, R. H. B. (2010) · Side effects of drugs annual · doi:10.1016/s0378-6080(10)32023-x
Kong, Y., Zhang, Z., Cai, Y., Zhao, Z., Zhang, X., Cheng, G., Li, X., & Cao, D. (2022) · SSRN Electronic Journal · doi:10.2139/ssrn.4140007
Pyridine-appended thiosemicarbazone complexes of iron: A complex mechanistic behaviour
Algarra, A. G., Castillo, C. E., Fernández‐Trujillo, M. J., Ferrer, M., Gonzálvez, M. A., Basallote, M. G., & Martı́nez, M. (2024) · Advances in inorganic chemistry · doi:10.1016/bs.adioch.2024.05.005
Mukherjee, P., Mukherjee, S., Khanra, S., Chatterjee, S., & Das, D. (2025) · ChemistrySelect · doi:10.1002/slct.202503757
Mousavi, Z., Ghasemi, J. B., Mohammadi Ziarani, G., Rahimi, S., & Badiei, A. (2024) · Figshare · doi:10.6084/m9.figshare.25670111
Wijesinghe, T. P., Dharmasivam, M., Kaya, B., Bernhardt, P. V., Naher, M., & Richardson, D. R. (2026) · Chemical Science · doi:10.1039/d6sc02195f
Self-citation
Metadata
- Authors
- Kalinowski, D. S., & Richardson, D. R.
- Affiliations
- The University of Sydney (AU)
- Corresponding author
- Richardson, Des R.
- Venue
- Chemical Research in Toxicology
- Publisher
- American Chemical Society (ACS)
- Published
- 2007-04-03
- Volume
- 20
- Issue
- 5
- Pages
- 715-720
- ISSN
- 0893-228X (ISSN-L)
- 1520-5010
- OpenAlex
- W2071434358
- Cited by
- 145
- References
- 15
- Citations by year
- 2026: 2 · 2025: 6 · 2024: 9 · 2023: 6 · 2022: 6 · 2021: 7 · 2020: 9 · 2019: 9 · 2018: 10 · 2017: 6 · 2016: 11 · 2015: 9 · 2014: 4 · 2013: 3 · 2012: 7
- FWCI
- 6.35
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Chemical Research in Toxicology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Iron Metabolism and Disorders
- Health Sciences › Medicine › Oncology › Metal complexes synthesis and properties
- Physical Sciences › Environmental Science › Health, Toxicology and Mutagenesis › Heavy Metal Exposure and Toxicity
- Keywords
- iron chelators, cancer chemotherapy, redox activity, hydrazone complexes, thiosemicarbazone complexes, iron chelation therapy
- MeSH terms
- Humans, Hydrazones, Iron Chelating Agents, Isoniazid, Pyridines, Pyridoxal, Structure-Activity Relationship, Thiosemicarbazones, Toxicology, Chelation Therapy, Iron Overload
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.